The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Non-covalent vs covalent BTK inhibitors in CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, discusses the use of covalent and non-covalent Bruton’s tyrosine kinase (BTK) inhibitors in chronic lymphocytic leukemia (CLL) in the first and second-line settings, commenting on their efficacy and toxicity profile. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
